AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$GRAL

Partridge Andrew John sold $91K of GRAL

Partridge Andrew John (Chief Growth Officer) sold 1,491 shares of GRAIL, Inc. (GRAL) at $61.08 on 2026-06-04.

Original reporting
SEC EDGAR · Partridge Andrew John
Published Jun 6, 2026, 12:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 6, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRAL
Neutral
medium confidence
Mentioned
$GRAL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRALNeutralLow
01

Why it matters

This adds a new datapoint on insider behavior but does not introduce new operational or financial information about GRAIL.

02

Market read

Traders may briefly reassess sentiment around GRAL due to insider selling, but the filing alone is unlikely to change valuation materially.

03

What to watch

The article doesn’t state whether other insiders bought/sold, whether there were concurrent grants, or the broader insider trading pattern; one sale is not a trend.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 5; sale occurred June 4.

Background

The article is an SEC Form 4 insider transaction disclosure for GRAIL, Inc. (GRAL).

Company-level read

Ticker impact

$GRALNeutralMedium confidence
Context

GRAIL insider Chief Growth Officer Partridge sold 1,491 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing provides a single sale datapoint without new company fundamentals (no guidance, trial, or deal). The absence of a 10b5-1 plan can increase interpretive noise, but the dollar amount (~$91k) is typically not material versus market cap.

Market effects

Sector

Minimal—this is company-specific insider activity with no stated sector-wide change.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may reflect diversification, liquidity needs, or tax planning rather than a bearish view, especially since insider transactions are often routine.

Key entities

  • issuer
    GRAIL, Inc.

    Public company whose insider transaction was reported on SEC Form 4.

  • insider
    Andrew John Partridge

    Chief Growth Officer who sold 1,491 shares on June 4 (reported via Form 4).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRAL insider trading history →

Related articles

$GRALMed

Her Doctor Will Order a $949 Blood Test That Screens for Multiple Cancers. Medicare Will Pay $0 Toward the Test, Leaving Her With the Entire Bill Before Any Coverage Decision in 2029

Grail's Galleri cancer-detection test, priced at $949, is not covered by Medicare. FDA advisory panel supported its effectiveness, safety, and risk-benefit profile. Medicare coverage may start in 2029, but age restrictions could exclude some beneficiaries. Grail expects FDA decision by early Q1 2027. Promotional pricing and other coverage options may reduce out-of-pocket costs.

247wallst.com
$GRALMed

GRAIL Inc (GRAL) (Q3 2026) Earnings Call Highlights: FDA Nod on the Horizon as Galleri

GRAIL (GRAL) reported Q3 2026 earnings, highlighting a pricing promotion that lowered ASPs to $660 to prioritize volume growth. The company expects FDA approval for Galleri to differentiate it from competitors and drive market bifurcation. GRAIL plans to engage CMS and commercial payers for reimbursement post-approval. International expansion is underway, with UKCA approval in the UK and IVDR submission in Europe. The sales force was expanded to 120 representatives, meeting Q3 volume goals.

finance.yahoo.com
$GRALMed

GRAIL (GRAL) Q3 2026 Earnings Call Transcript

GRAIL (GRAL) reported Q3 2026 revenue of $37.5M, up 4% YoY. Test volumes rose 24% YoY to 56,000. FDA advisory committee voted positively on Galleri, a multi-cancer early detection test, with a final decision expected by early Q1 2027. Clinical studies showed Galleri's ability to detect 140+ cancer types with low false positives. Commercial traction continues with 36% YoY volume growth in the first 9 months of 2026.

finance.yahoo.com
$GRALMedAI 8/10

What GRAIL (GRAL) Said on Its Q3 Earnings Call

GRAIL (GRAL) reported Q3 revenue of $37.3M, up 14%, with test volume increasing 24%. Adjusted gross margin fell to 42% from 55% YoY. The company maintained 2026 cash burn guidance of no more than $300M. GRAIL cited clinical study results showing increased cancer detection and reductions in advanced-stage diagnoses. They expect FDA approval to support reimbursement efforts.

finance.yahoo.com
$GRALMed

Grail tumbles as revenue misses estimates despite FDA vote

Grail Inc (GRAL) reported Q3 revenue of $37.5M, missing estimates by 17%. The company posted a loss of $2.21 per share, with revenue up 4% YoY. Galleri test revenue grew 14% YoY to $37.3M. Stock fell 11.5% in after-hours trading. FDA Advisory Committee voted in favor of Galleri test approval. GRAL anticipates an FDA decision by early Q1 2027. Q3 net loss was $103.6M, up from $89.0M YoY.

investing.com